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Edited by Felix WielandAbstract Physiological and pathological states that are asso-
ciated with elevated plasma fatty acids (FAs) increase uncou-
pling protein 2 (UCP2) mRNA in white adipose tissue and UCP3
mRNA in skeletal muscle and heart. A direct eﬀect of
unsaturated fatty acids from all classes has been shown in
various cultured cells. There is evidence that FAs could induce
expression of UCPs by acting as ligands for peroxisome
proliferator-activated receptors, inﬂuencing the function of sterol
responsive element binding protein or activating 50-AMP-
activated protein kinase. Oleic acid has been shown to stimulate
the activity of the promoter regions of UCP2 and UCP3 genes
and the FA responsive regions are beginning to be characterised.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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UCP2 and UCP3, members of the uncoupling family of
proteins, are of interest because of their potential roles in
regulating energy expenditure and thus contributing to obesity
and type 2 diabetes, and hypermetabolic states such as those
associated with sepsis, cancer cachexia and hyperthyroidism.
The uncoupled proteins (UCPs) are found in the inner mi-
tochondrial membrane and are able to uncouple the oxidation
of fuels via the electron transport chain from ATP synthesis,
thus dissipating energy as heat and potentially aﬀecting met-
abolic eﬃciency. The most well-known member of the family is
UCP1, which is uniquely expressed in brown adipose tissue
and plays an important role in cold- and diet-induced ther-
mogenesis (reviewed in [1]). UCP2 and UCP3 were ﬁrst cloned
and identiﬁed in humans in 1997 and subsequently in rodents* Corresponding author. Fax: +64-3-4797866.
E-mail address: mary.thompson@stonebow.otago.ac.nz
(M.P. Thompson).
Abbreviations: AICAR, 5-aminoimidazole-4-carboxamide-1-b-D-ribo-
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doi:10.1016/j.febslet.2004.05.011[1]. They share about 56% amino acid identity with UCP1 and
are themselves about 72% identical. UCP2 and UCP3 do not
appear to be solely involved in thermogenesis, and have pro-
posed roles in modulating generation of reactive oxygen spe-
cies and in lipid handling, although their physiological roles
have not yet been deﬁnitively determined. UCP2 mRNA is
found in many tissues and at high levels in white adipose tis-
sue, skeletal muscle, spleen and pancreatic b-cells, whereas
UCP3 is predominantly expressed in skeletal muscle, heart,
and to a lesser extent adipose tissue. This expression pattern is
consistent with their proposed roles since adipose tissue and
skeletal muscle are major contributors to overall energy me-
tabolism. Variations in activity or regulation of UCP2 and
UCP3 in these tissues could contribute to obesity and associ-
ated diseases.
Considerable eﬀort has gone into determining how the ex-
pression of UCP2 and UCP3 is regulated. It turns out that the
various physiological and pathological states that are associ-
ated with raised levels of UCP2 and UCP3 mRNAs in adipose
tissue and skeletal muscle are all characterised by elevated
plasma fatty acid (FA) levels. This has led to the hypothesis
that FA themselves are the molecular signals that bring about
the changes in UCP2 and UCP3 expression.
Understanding this link between FA and UCP2 and UCP3
expression could provide new information about how pro-
cesses related to energy metabolism are controlled in health
and disease. Here, we review the evidence for this link and the
progress towards determining the molecular mechanisms by
which FA bring about transcriptional upregulation of UCP2
and UCP3 mRNA expression (overview in Fig. 1). Functional
consequences of such regulation of their mRNA levels are not
known at this stage and would depend on protein levels and
activities.2. In vivo regulation of UCP2 and UCP3 is linked with FAs
A number of physiological and pathological states lead to
increased expression of UCP2 and UCP3 mRNAs. These in-
clude fasting [2–13], high-fat diets [14–19], suckling of newborn
pups [20], sepsis [21,22], acute endurance exercise [23–27], and
hyperthyroidism (reviewed in [28]), as well as experimental
manipulations such as lipid infusion [5,21,29,30] and strepto-
zotocin-induced diabetes [11,32,33]. A common feature of all
these conditions is a 2- to 3-fold elevation in plasma FA. The
eﬀects of these conditions on the expression of UCP2 and
UCP3 mRNAs in various tissues are summarised in Table 1.blished by Elsevier B.V. All rights reserved.
Fig. 1. Molecular routes by which FA could increase the expression of UCP2 and UCP3 mRNAs. Physiological and experimental manipulations
(blue) that elevate plasma FA also increase UCP2 and UCP3 mRNAs in a tissue-dependent manner. The changes in mRNA levels need not correlate
with changes in protein levels; possible post-transcriptional regulation remains to be studied. Experimental activation of PPARs and AMPK (purple)
also increases UCP2 and UCP3 mRNAs. Unsaturated FA could work by activating certain PPARs, inﬂuencing SREBP1 function, or via other, as
yet unidentiﬁed, transcription factors (TF) by stimulating AMPK or the hexosamine pathway.
Table 1
Change in expression of UCP2 and UCP3 mRNAs in response to physiological and experimental states in vivo
Conditiony Skeletal muscle Heart White adipose
tissue
Brown adipose
tissue
Liver
Fasting UCP2 $[3,5], " [2,6,8,10] $ [2,11,12] # [13] $ [3,9], " [8] $ [13], " [8]
UCP3 " [2–10] " [11] # [3,9]
High-fat diet UCP2 $ [15–18] " [14–18] $ [15] " [17,19]
UCP3 " [15–17], $ [18] $ [15–17] $ [15]
Streptozotocin
induced diabetes
UCP2 $ [33], " [31,32] $ [11,12] " [32], $ [31] " [32], $ [31]
UCP3 " [31–33] " [11] $ [32] $ [32], # [31]
Sepsis and inﬂammation UCP2 " [22] " [22] " [22]
UCP3 " [21]
Acute exercise UCP2 $ [24,27]* $ [23]
UCP3 " [23-25,25]
Intralipid infusion UCP2 $ [29]* $ [29]*, " [30]*
UCP3 " [5,21,29]* " [30]*
Change of expression of mRNA: ", increased; #, decreased;$, no change; *, human subjects;  all these conditions are associated with a 2- to 3-fold
elevation of plasma FA. References are given in parentheses.
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diﬀerences in muscle types sampled, nature of the dietary fats,
length of feeding regimes or strains of animals. Despite the
incomplete or conﬂicting reports, taken together there seem to
be tissue-dependent trends. In skeletal muscle and heart, the
trend is for increased UCP3 mRNA with little change of UCP2
mRNA, whereas in white adipose tissue, the trend is for in-
creased UCP2 mRNA with little change in UCP3 mRNA. For
brown adipose tissue, the trend is for decreased UCP3 mRNA.
Similar observations have also been made in the limited
number of studies on human subjects. For example, infusion
with intralipid [29] or acute endurance exercise [27] increased
UCP3 mRNA with no change in UCP2 mRNA in skeletal
muscle biopsies from human subjects. A positive linear cor-
relation was found between plasma FA and UCP3 mRNA in
muscle biopsies from obese human subjects, but not with
UCP2 mRNA [34,35].
All these in vivo studies point to a link between FA and
expression of UCP2 and UCP3 that occurs in a tissue-depen-
dent manner. This may be related to distinct physiological
roles of UCP2 and UCP3 in diﬀerent tissues.3. Fatty acids directly aﬀect expression of UCP2 and UCP3 in
cultured cells
Studies conducted in vitro using cultured cell models or pri-
mary isolated cells provide the most convincing support for a
direct eﬀect of FA or their metabolic derivatives on UCP2 and
UCP3 expression. These studies are summarised in Table 2.
Myoblast cell lines derived from mouse (C2C12), rat (L6)
and human muscle can be induced to diﬀerentiate into myo-
tubes and are commonly used as in vitro models of muscle.
Many studies using myotubes have shown that the mono-un-
saturated 18:1(n 9) and polyunsaturated FA of both the
n 6 and n 3 class, added directly to the culture medium at
physiological concentrations, increase the expression of UCP3
[7,35–40], with no increase in UCP2 mRNA [35,40]. These
ﬁndings parallel the pattern seen most commonly in skeletal
muscle in vivo. However, others found that downstream me-
tabolites of linoleic acid (18:2), linolenic acid (c18:3), 20:3 and
arachidonic acid (20:4) did induce UCP2 in human primary
myotubes, whereas 18:2 itself did not [42]. (UCP3 was not
measured in these studies.)
Table 2
Observed eﬀects of diﬀerent classes of FAs on expression of UCP2 and
UCP3 mRNAs in cultured cells
UCP2 UCP3
16:0 "INS-1* [46]
n 9 18:1 $ hSM [42] " hSM [35]
$ C2C12 [40] " C2C12 [7,40]
" 3T3-L1 [43] " L6 [36–39]
"INS-1 [46,47]
" hepatocytes [45]
" cardiomyocytes [12]
n 6 18:2 $ hSM [35,42] " hSM [35]
$ C2C12 [40] " C2C12 [40]
" L6 [41] " L6 [38]
" 3T3-L1 [43]
" Ob1771 [44]
c18:3 " hSM [42]
20:3 " hSM [42]
20:4 " hSM [42]
"hepatocytes [45]
n 3 a18:3 $ C2C12 [40] " C2C12 [40]
" 3T3-L1 [43]
20:5 " 3T3-L1 [43]
"hepatocytes [45]
Expression of UCP2 or UCP3: ", increased; $, no change. Cell lines:
hSM, human skeletal muscle myotubes; C2C12, mouse myotubes; L6,
rat myotubes; 3T3-L1 and Ob1771, preadipocytes; INS-1, b-cell line; *,
no other cell lines have been reported to show upregulation of UCP2
or UCP3 in response to saturated FA. References are given in
parentheses.
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each of the diﬀerent classes (n 9; n 6; n 3) markedly in-
duced UCP2 mRNA [43,44]. A number of other cultured cell
systems representing heart, liver, and pancreatic islets also
responded to addition of various FA to the culture medium
with increased levels of UCP2 mRNA [12,45–47]. The INS-1
cell line, derived from islet b-cells, is the only one so far to
show responsiveness to a saturated FA [46].
The response to FA is most likely due to increased tran-
scription. At least one study has shown that addition of acti-
nomycin D, an inhibitor of transcription, prevented the
increase of UCP2 mRNA in 3T3-L1 pre-adipocytes by 18:2,
with no eﬀect on turnover [43]. It is possible that actinomycin
D prevented transcription of other FA-responsive genes that
are required for regulation of expression of UCPs. Additional
post-transcriptional regulation by FA cannot be ruled out.
From these studies, it is clear that all classes of unsaturated
FA and/or their metabolism can directly bring about the up-
regulation of UCP2 and UCP3 mRNAs in cultured cells. This
apparent lack of speciﬁcity for the FA that cause induction
seems surprising. It suggests that FA per se are the regulators
rather than a speciﬁc secondary metabolite derived from a
particular pathway. The response is dependent upon the cell
type and supports the likelihood of tissue-speciﬁc diﬀerences in
the signalling mechanisms regulating UCP2 and UCP3 ex-
pression in response to FA. The tissue-speciﬁc complement of
transcription factors and/or unique response elements in the
regulatory promoter regions of the UCP2 and UCP3 genes
could contribute to these distinct patterns of regulation.4. Do fatty acids work via PPARs?
A family of transcription factors that could be involved in
mediating the eﬀect of FA are the peroxisomal proliferator-activated receptors (PPARs). There is already good evidence
that FA induce transcription of a cohort of genes involved in
lipid oxidation in liver and adipose tissue by acting as ligands
of PPARs [48]. It is possible that UCP2 and UCP3 belong to
this cohort of genes as their increased expression could po-
tentially increase FA oxidation. Upregulation of UCPs by FA
might also be via PPARs. All the classes of unsaturated FA
(n 9; n 6; n 3) that have been shown to induce either
UCP2 or UCP3 in at least one in vitro experimental cell culture
system have also been shown to act both as ligands and acti-
vators for all three main isoforms of PPARs [49]. Other known
synthetic PPAR ligands are able to upregulate UCP2 and
UCP3. The pattern of upregulation by selective PPAR ligands
in cultured cells matches the predominant tissue-selective ex-
pression of the PPAR isoforms: via PPARc in adipose tissue
[44,50–52], via PPARd in muscle [36,38,53] and via PPARa in
liver [19,45]. Ligands for RXR, which forms the active hete-
rodimer with PPARs, can also enhance UCP3 transcription in
cultured muscle cells [36,38,54]. All these observations are
consistent with, although not deﬁnitive proof of, FA acting via
PPARs to upregulate UCP2 and UCP3, and also suggest that
this may occur in a tissue-speciﬁc manner via diﬀerent PPAR
isoforms.5. Do FA work via SREBP1?
The sterol responsive element (SRE) binding protein
(SREBP) family of transcription factors are known for their
role in regulating lipid metabolism [55]. SREBP1 induces the
expression of genes involved in lipid synthesis in liver and
adipose tissue. Interestingly, polyunsaturated FA repress the
expression of these same genes [48] and this appears to occur
via a mechanism involving SREBP1. Polyunsaturated FA de-
crease the expression of SREBP1 mRNA and decrease the
level of the proteolytic fragment of SREBP1 that enters the
nucleus as the active transcription factor, thus decreasing
the ability of SREBP1 to activate transcription of the SREBP-
responsive lipogenic genes in liver [56,57]. UCP2 and UCP3
are unlikely to belong to this group of lipogenic genes because
all conjecture so far give UCPs a role in lipid oxidation.
However, SREBP1 has recently been shown to repress the
expression of some genes [58]. Is it possible that SREBP1 could
also repress UCP2 and/or UCP3 (perhaps in tissue-speciﬁc
way), and thus when FA decrease SREBP1 activity, repression
would be relieved and the expression of UCPs increased? Is
there any evidence for this possibility?
As yet there is no direct evidence that SREBP1 represses
UCP2 or UCP3 expression, although there are several situa-
tions where SREBP1 levels are inversely associated with UCP2
or UCP3 mRNA levels in adipose tissue [59,60] and skeletal
muscle [33,61], respectively. These observations support the
notion that SREBP1 may repress expression of UCP2 and
UCP3. However, data that are contrary to this hypothesis were
obtained from INS-1 cells transformed with the active form of
SREBP1c; genes of lipogenesis were induced as expected and
UCP2 mRNA was also apparently increased, although this
was not quantitatively analysed [62]. Involvement of SREBP1
as an activator of UCP2 is also suggested by studies of UCP2
promoter activity, again in INS-1 cells, where cotransfection of
the active SREBP1c enhanced expression of a luciferase re-
porter driven by UCP2 promoter [47]. If all these observations
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and its involvement in FA regulation of UCP2 and UCP3
expression must depend upon other tissue-speciﬁc factors as
well.6. By what other mechanisms could fatty acids induce UCPs?
Another route, which is yet to be fully explored, by which
FA could inﬂuence gene expression is via activation of the
energy-sensing 50-AMP-activated protein kinase (AMPK)
[63]. AMPK could be activated by the AMP generated by
conversion of FA to their CoA derivatives during metabo-
lism. Active AMPK in turn may bring about phosphorylation
of certain transcription factors and thereby alter UCP2 and
UCP3 expression. Experimental activation of AMPK by the
AMP analogue 5-aminoimidazole-4-carboxamide-1-b-D-ribo-
furano- side (AICAR) has been shown to increase UCP3
mRNA in skeletal muscle in vivo [64–66] and in vitro [25,67].
UCP2 expression in INS-1 cells has also been shown to be
responsive to AICAR treatment [68]. The missing molecular
links are whether FA metabolism does in fact activate
AMPK and whether transcription factors that are targets
of AMPK are involved in regulating UCP2 and UCP3
expression.
FA metabolism could also inﬂuence the metabolism of
glucose and change ﬂux through the hexosamine pathway,
which has a role as a nutrient sensor [69]. Elevated levels of
hexosamines may in turn lead to O-glycosylation of proteins
involved in various aspects of gene expression. This potential
mechanism for upregulation of UCPs by fatty acids remains to
be studied.7. Can fatty acid responsive regions be identiﬁed in the promoters
of UCPs?
Some progress is beginning to be made in identifying regions
within the 50-upstream regulatory region (50-USR) of the
UCP2 and UCP3 genes that confer FA responsiveness. Tran-
scription factors that bind to sites within this region might be
identiﬁed by computer-assisted analysis and ultimately by
functional analysis. If FA work via PPARs or SREBP1, then
binding sites for these factors might be expected within this
region. However, such FA responsive regions are proving
elusive.
7.1. UCP2 promoter
The ﬁrst demonstration that FA can increase transcriptional
activity of the UCP2 promoter was made in INS-1 cells tran-
siently transfected with a luciferase reporter driven by the 50-
USR of mouse UCP2 gene [47]. Treatment of these cells with
oleic acid (18:1) caused a 2-fold stimulation of luciferase ac-
tivity. This increase in promoter activity was consistent with a
similar increase of endogenous UCP2 expression in the same
cell line in response to 18:1 [46,47]. The region responsible for
conferring FA responsiveness to the reporter was narrowed
down to 42 bp near the transcription start site. Computer-as-
sisted analysis of this region identiﬁed a putative Sp1 site, a
putative SRE motif and two E-box motifs. Mutations of the
SRE site or either of the E-boxes eliminated the response of theUCP2 promoter to 18:1, suggesting that this region corre-
sponded to a FA responsive region. If FA are regulating UCP2
expression via this region, then transcription factors that can
bind to them would in turn need to be inﬂuenced by FA.
Transcription factors to be considered are SREBP1, upstream
stimulatory factor 1 (USF1) and USF2, which were shown to
bind to this region [47], and also PPARc, which appears to act
indirectly via this same region [70]. A mechanism by which FA
regulate these transcription factors needs to be determined. FA
could activate PPARc by acting as ligands. Currently, there is
no evidence for FA activating or inducing SREBP1; to the
contrary, there is evidence that polyunsaturated FA actually
downregulate SREBP1, at least in liver [56]. Nevertheless,
there appears to be a connection between SREBP1 and FA
responsiveness in INS-1 cells as over-expression of active
SREBP1c, together with 18:1 treatment, leads to further aug-
mentation of UCP2 promoter activity beyond the eﬀect of ei-
ther one alone [47], but the mechanism for this remains to be
determined. It will be important to study the promoter activity
of 50-USR of UCP2 in other cells representative of adipose,
muscle and liver to establish if SREBP1 eﬀects are tissue-
dependent.
7.2. UCP3 promoter
The problem of choosing a suitable cell line in which to
functionally analyse promoter regions is again highlighted for
UCP3. Substantial basal expression of luciferase reporter dri-
ven by the 50-USR of human UCP3 in an L6 muscle cell line
required cotransfection with MyoD [71]. This observation is
consistent with UCP3 being expressed highly in diﬀerentiated
muscle cells, which are characterised by high levels of MyoD, a
muscle-speciﬁc transcription factor. Incubation of L6 myo-
blasts with 18:1 increased up to 2-fold the expression of the
transfected reporter driven by 50-USR of human UCP3, but
this also required cotransfection with either PPARa or PPARd
as well as with MyoD [71]. The requirement for MyoD along
with a requirement for PPARa or d suggests that these tran-
scription factors functionally interact to bring about FA re-
sponse. The responsiveness to PPAR agonists via PPARa
required an intact direct repeat (DR1) element and MyoD
induction depended on E boxes within 165 bp of the tran-
scription start site [71]. It remains to be shown in transient
transfection assays whether the responsiveness to 18:1 is also
retained within this 165 bp 50-USR and whether the DR1 re-
peat element or E-boxes are critical for FA regulation of
UCP3. Interestingly, somatic transfer of reporter constructs
into the hindlimb of newborn mice showed that an intact DR1
element was required for induction of the promoter by suck-
ling [71]. This provides indirect support for the DR1 element
also being involved in FA regulation, as suckling is a situation
that is accompanied by elevated plasma FA and induction of
endogenous UCP3 [20].8. Missing links between FA and UCP2 and UCP3 expression
The many studies reviewed here point to unsaturated FAs as
key regulators of UCP2 and UCP3 expression in response to
changes in nutritional status and whole body energy metabo-
lism. The mechanisms by which FAs upregulate UCP2 and
UCP3, in what appears to be a tissue-speciﬁc manner, have not
yet been fully determined. Further work is required to ﬁnd:
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speciﬁc responses to FA; the transcription factors involved and
how FA inﬂuence their function; the molecular route by which
FA induce UCP2 in adipose tissue but not in muscle, and
UCP3 in muscle but not in adipose tissue; how regulation is
associated with the physiological roles of the UCPs in the
diﬀerent tissues; whether regulation is abnormal in various
pathological states.
All this work will be worthwhile because there remains the
enticing possibility of identifying novel targets in the molecular
chain of events that are amenable to therapeutic intervention
by new drugs, or even dietary manipulation, to control obesity,
type 2 diabetes and other disorders of energy metabolism.References
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